Research Progress of Immunoscore in Prediction of Tumor Prognosis and Efficacy to Treatment / 肿瘤防治研究

The occurrence and development of the tumor are closely associated with the tumor microenvironment (TME) and host immune status. Traditional TNM staging has gradually been insufficient in the assessment of patients' outcomes, as the TNM system solely evaluated tumor cell characteristics and failed to predict clinical outcomes based on immune factors. Therefore, immunoscore (IS), derived from the concept of immune contexture, was proposed to establish a more comprehensive and accurate TNM-I staging above the TNM staging. Recently, increasing studies have shown that IS can predict the survival outcome and treatment efficacy more accurately than TNM staging. Moreover, IS possess characteristics such as feasibility, convenience, robustness and reproducibility, which make it possible for IS to be used as a biomarker for clinical application, to classify patients better and contribute to developing individualized treatment strategies, ultimately, to improve the overall survival of patients with cancer. This article reviews of the progress of immunoscore in predicting patients' prognosis and response to therapy among different tumors.

Research progress in Immunescore system in tumor prognosis / 医学研究生学报

Tumor is one of the most common diseases threatening human health, morbidity and mortality of which are on the rise. At present, TNM staging system is widely used to evaluate the prognosis of patients, but this system has been challenged. Emerging evidence shows that post-operative patients with same TNM stage may exhibit significantly discrepant survival. New classification methods based on tumor cell type, molecular pathways, mutation status and tumor gene expression only exhibit moderate prediction accuracy and limited clinical use. Recently, various studies have shown that Immunoscre can predict the prognosis of patients with colorectal cancer more accurately and guide personalized therapy better. This article introduces the establishment and development of Immunoscore system, and reviews the value, advantages and problems in guiding treatment.

Research progress on tumor immune microenvironment evaluation in efficacy predic-tion / 中国肿瘤临床

With the clinical applications of new immunotherapies, traditional TNM staging has been unable to meet the clinical needs of curative effect predictions. It is known that the immunological features of the tumor immune microenvironment play important roles in tumor prognosis evaluations. Recently, the immunoscore system, which is based on local immune cell distribution and density, has gradually become an important indicator for prognosis evaluations and has been verified in several tumor researches. Recently, with the application of new mass flow detection and single cell sequencing technologies, the number of immune landscape studies have also been increasing, and new tumor-specific immune cell subsets have been identified. These subtypes not only provide individ-ualized immunotherapy guidelines for patients, but also provide potential new targets for the further development of new immuno-therapy strategies. This review will introduce recent research progress in this field.

Research progress of immunoscore / 国际肿瘤学杂志

A methodology named immunoscorehas been proposed in recent years.It has been demonstrated to be a prognostic factor superior to the Union for International Cancer Control-American Joint Committee on Cancer (UICC-AJCC)TNMclassification.Over the past few years,it has gained a forefront posi-tion in colorectal cancer.It has the advantages of simple operation,low cost and high accuracy,and it is nee-ded for individual therapy.However,it still has its limitations.